Babbula: Traditional Use, Evidence & Safety

TL;DR

Babbula is the dried bark of Acacia nilotica (now Vachellia nilotica), a pharmacopoeial Ayurvedic drug. The human evidence is mostly dental and small: one trial found an acacia gel improved gingivitis like chlorhexidine, and a mouthwash cut oral bacteria. Evidence for internal use is thin, and safety data are limited.

What it is

Babbula is the dried mature stem bark of Acacia nilotica (Linn.) Willd. ex Del. sp. indica (Benth.) Brenan, synonym Acacia arabica Willd., family Leguminosae, a moderate-sized, spiny, evergreen tree found throughout India. It is monograph 15, "Babbula (St. Bk.)", in the Ayurvedic Pharmacopoeia of India, Part I, Volume I, a Government of India publication (monograph text: public document mirror). Botanists have since reclassified the species as Vachellia nilotica (L.) P.J.H. Hurter & Mabb., with Acacia nilotica retained as the taxonomic synonym, a shift documented in a 2024 Nutrients review of the plant (Nutrients 2024 review).

The pharmacopoeial monograph describes the bark as hard, dark brown or black, deeply fissured, with an astringent taste, and lists its constituents simply as tannins and gum (API monograph: public document mirror).

Traditional use

The Ayurvedic Pharmacopoeia of India lists babbula's traditional therapeutic uses as kuṣṭha (skin disorders), kṛmiroga (worm infestation), atisāra (diarrhoea), and kāsa (cough), and names formulations containing it such as Babbūlāriṣṭa and Mṛtasañjīvanī Surā (API monograph: public document mirror). Ethnobotanical reviews record its long use in Ayurvedic and Unani practice, for which tannin-rich astringent bark was prized (Nutrients 2024 review). These are records of traditional and pharmacopoeial use, not clinical proof. The human-trial evidence is assessed separately below.

What modern research says

Gingivitis (randomized, placebo- and positively-controlled trial)

This is the strongest trial babul has. In a prospective, randomized, placebo- and positively-controlled clinical trial, 90 people with chronic generalized gingivitis were assigned to a commercial Acacia arabica gel (Gumtone), a placebo gel, or a 1% chlorhexidine gel, with gingival-index and plaque-index scores measured at baseline and at 2, 4, and 6 weeks (Pradeep et al., Aust Dent J 2010). The acacia gel showed significant clinical improvement in gingival and plaque index scores compared with placebo, comparable to the chlorhexidine gel, and without the teeth discolouration or unpleasant taste reported with chlorhexidine. I find that last detail interesting. Single small trial, 6 weeks: promising, not conclusive.

Toothpaste (randomized, double-blind crossover trial)

In a randomized, double-blind crossover trial, 60 adults with gingivitis brushed with an Acacia arabica-containing toothpaste or a regular toothpaste for 28 days, then crossed over after a washout period. Plaque index, gingival index, and bleeding-on-probing were recorded (Tangade et al., Chin J Dent Res 2012). Reductions in plaque, gingival, and bleeding scores were observed with the acacia toothpaste compared with the regular toothpaste.

Mouthwash against cavity-causing bacteria (double-blind RCT)

In a double-blind, randomized controlled trial, 90 high-caries-risk volunteers rinsed twice daily for 30 days with 10 ml of 50% A. nilotica, 0.2% chlorhexidine, or saline, with saliva sampled at baseline and at 30 and 60 days (Gupta & Gupta, Gen Dent 2015). Salivary mutans streptococci colony counts fell by 85% in the acacia group and 83% in the chlorhexidine group at 30 days, and by 65% versus 63% at 60 days (P < 0.0001), an antibacterial action the authors found similar to chlorhexidine. Read carefully, though: this measures bacteria in saliva, not actual cavity prevention.

What about bacterial vaginosis?

There is no verifiable human evidence that babbula bark decoction treats bacterial vaginosis. A 2014 randomized trial comparing bark decoction with metronidazole is cited in some reviews, but its full paper could not be located and independently checked, so its results are not repeated here. A separate, primary trial (2022) tested Acacia nilotica pods, a different plant part and a topical route, as a sitz bath plus vaginal pessary versus placebo for syndromic abnormal vaginal discharge. Within its small bacterial-vaginosis subgroup, 7 of 7 women in the acacia group achieved therapeutic cure versus none in placebo (Saeedi et al., Evid Based Complement Alternat Med 2022). That is a tiny subgroup finding about pods used topically, not a basis for treating BV with bark decoction.

What the evidence does not support (yet)

Nearly everything else attributed to babul, effects on blood pressure, blood sugar, infections, wounds, and more, comes from animal or laboratory studies, not human trials. The 2024 Nutrients review states plainly that human clinical trials are scarce, and that the most robust evidence concerns microbial infections, diarrhoea, wound healing, and topical application (Nutrients 2024 review).

Dosage

The Ayurvedic Pharmacopoeia of India gives the dose as 20–30 g of the drug for decoction, a pharmacopoeial standard, not a personal recommendation (API monograph: public document mirror). No other established dose exists. The dental trials used topical preparations (gel, toothpaste, or a 10 ml 50% mouth rinse), not oral dosing.

Safety

Human safety data for babbula bark are limited. The published trials reported efficacy outcomes, not systematic safety data, and none was designed as a safety study; long-term safety has not been studied. Because the only internal-use standard is a pharmacopoeial decoction dose, anyone considering internal use, especially during pregnancy or alongside prescription medicines, should consult a qualified practitioner first.

FAQs

What is babbula?

Babbula is the dried mature stem bark of Acacia nilotica (also called Acacia arabica, now reclassified as Vachellia nilotica), a spiny evergreen tree found across India. It is monograph 15 in the Ayurvedic Pharmacopoeia of India, Part I, Volume I (API monograph: public document mirror).

Does babbula help with gum disease?

Possibly. In a randomized trial of 90 people with chronic generalized gingivitis, an Acacia arabica gum gel significantly improved gingival and plaque index scores versus placebo gel, comparable to 1% chlorhexidine gel (Pradeep et al., Aust Dent J 2010). This is a single small 6-week trial, not proof.

Can babbula mouthwash reduce cavity-causing bacteria?

In one double-blind trial (n=90), a 50% A. nilotica rinse used twice daily for 30 days reduced salivary mutans streptococci counts similarly to 0.2% chlorhexidine (Gupta & Gupta, Gen Dent 2015). That is a bacterial-count result, not demonstrated cavity prevention.

Can babbula treat bacterial vaginosis?

No verifiable human evidence supports babbula bark for bacterial vaginosis. A frequently cited 2014 bark-decoction trial could not be independently verified, so its results are not repeated here. One small primary trial of acacia pod sitz bath plus pessary (a different part and route) reported cure in 7 of 7 women in its BV subgroup, too small and too different to act on (Saeedi et al., 2022). BV should be diagnosed and treated under medical supervision.

What dose does the pharmacopoeia give?

The Ayurvedic Pharmacopoeia of India gives 20–30 g of the drug for decoction (API monograph: public document mirror). That is an official standard, not a recommendation for self-dosing.

Is babbula safe?

Human safety data are limited: the published trials reported efficacy outcomes, not systematic safety data, and long-term safety has not been studied. Consult a qualified practitioner before internal use, especially in pregnancy or with prescription medicines.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use, especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.